1. Home
  2. PRSO vs BLRX Comparison

PRSO vs BLRX Comparison

Compare PRSO & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peraso Inc.

PRSO

Peraso Inc.

HOLD

Current Price

$0.30

Market Cap

13.4M

Sector

Technology

ML Signal

HOLD

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$1.18

Market Cap

11.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRSO
BLRX
Founded
2008
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.4M
11.7M
IPO Year
2000
2010

Fundamental Metrics

Financial Performance
Metric
PRSO
BLRX
Price
$0.30
$1.18
Analyst Decision
Analyst Count
0
0
Target Price
N/A
★ $22.00
AVG Volume (30 Days)
★ 11.7M
8.8K
Earning Date
11-12-2026
12-01-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 81.23
N/A
EPS
N/A
★ N/A
Revenue
★ $14,573,000.00
N/A
Revenue This Year
N/A
$37.33
Revenue Next Year
$191.73
$37.06
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 5.99
N/A
52 Week Low
$0.28
$1.14
52 Week High
$2.10
$3.95

Technical Indicators

Market Signals
Indicator
PRSO
BLRX
Relative Strength Index (RSI) 36.98 21.15
Support Level N/A N/A
Resistance Level $0.46 $3.04
Average True Range (ATR) 0.04 0.14
MACD -0.01 -0.05
Stochastic Oscillator 10.38 16.72

Price Performance

Historical Comparison
PRSO
BLRX

About PRSO Peraso Inc.

Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: